Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

<h4>Background</h4> <p>Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective treatments for active rheumatoid arthritis (RA) but to date no randomised controlled trials have directly compared their safety, efficacy and cost effectiveness. This study wa...

Full description

Bibliographic Details
Main Authors: Porter, D, van Melckebeke, J, Dale, J, Messow, C, McConnachie, A, Walker, A, Munro, R, McLaren, J, McRorie, E, Packham, J, Buckley, C, Harvie, J, Taylor, P, Choy, E, Pitzalis, C, McInnes, I
Format: Journal article
Language:English
Published: Elsevier 2016

Similar Items

Similar Items